Articles

Poll

Podcasts

Slideshows

Videos

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Chedid describes the future of personalizing IBD care based on patient characteristics. 

Persistent Symptoms, Equity Gaps, Pushing For Whole-Person IBD Care, With Victor Chedid, MD, MS

Catch up on new IBD drug trial data, regulatory actions, and updates in IBS in this April month in review.

5 Gastroenterology Headlines You Missed in April 2026

Despite a growing armamentarium of approved IBD therapies, outcomes remain suboptimal. Rubin explains how earlier treatment and smarter optimization can close the gap.

Closing the Gap Between IBD Therapies and Patient Outcomes, With David Rubin, MD

Laurent Peyrin-Biroulet, MD, PhD, breaks down FUZION data demonstrating meaningful fistula healing with guselkumab in Crohn’s disease patients with perianal disease.

Phase 3 FUZION Data Support Guselkumab in Perianal Fistulizing Crohn’s Disease

Routine depression and anxiety screening in IBD clinics was tied to significantly more referrals and sustained follow-up with psychogastroenterology services

Mental Health Screening in IBD Linked to Increased Psychogastroenterology Uptake

1-year results from ASPIRE-CD suggest risankizumab (Skyrizi) improves HRQL, well-being, and treatment satisfaction in adults with Crohn's Disease.

Risankizumab’s 1 Year Crohn's Disease Improvement in HRQL and Wellbeing in ASPIRE-CD

Edward Barnes, MD, MPH, explains mirikizumab’s strong remission and durable response in Crohn’s disease patients after anti-TNF failure, supporting second-line use.

VIVID Post Hoc Analysis Supports Mirikizumab After Anti-TNF Failure in Crohn’s Disease

Maria Abreu, MD, breaks down efficacy and safety data for dual-target co-antibody JNJ-4804, offering a potential new option for heavily pretreated UC patients.

DUET-UC Data Highlight Potential of Dual-Pathway Targeting in Refractory Ulcerative Colitis

The phase 3 FUZION trial found guselkumab achieved increased fistula remission rates than placebo in perianal fistulizing Crohn's disease.

Guselkumab Shows Efficacy in Perianal Fistulizing Crohn's Disease in Phase 3 FUZION Trial

JNJ-4804 phase 2b results showed higher week-48 remission rates in refractory ulcerative colitis and Crohn disease.

JNJ-4804 Phase 2b Data Show Higher Week-48 Remission in Refractory UC, Crohn Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Inflammatory Bowel Disease